Common Name1Factor Number2Function(s) FibrinogenIPrecursor to polymer, fibrin clot ProthrombinII3Precursor to thrombin ThromboplastinIII4Tissue homogenate that contains tissue factor and phospholipids; products of recombinant tissue factor and synthetic lipids are also available ...
BLOOD coagulation factor VIIITreatment for haemophilia A has expanded from plasma-derived factor VIII (pdFVIII) and standard half-life (SHL) recombinant FVIII (rFVIII) to extended half-life (EHL) rFVIII and non-factor products that mimic FVIII activity.#To determine amounts of clotting factor ...
from Chapter 19/ Lesson 11 49K Explore PT vs. PTT as blood tests for clotting disorders. Learn about blood clotting in the body, different clotting factor tests, and how to interpret the results. Related to this Question Explor...
Role of endothelial cell extracellular signal-regulated kinase ½ in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. J Cell Sci. 1999;112:2597–606.PubMed Gordon SG. Cancer cell procoagulants and their implications. Hematol Oncol Clin ...
Re- combinant clotting factor VIII concentrates: heterogeneity and high-purity evaluation. Electrophoresis 2010;31:2730-9.D'Amici GM, Timperio AM, Gevi F, et al. Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation. Electrophoresis, 2010, 31(16): 2730-2739....
Despite weight-based dosing, it has been demonstrated that factor concentrates still exhibit considerable pharmacokinetic variability. Population pharmacokinetic analyses, in which this variability is quantified and explained, are increasingly performed in hemophilia research. These analyses can assist in the ...
Optimal yields (0.72-0.78 x 10(11) platelets), separation efficiency (67.7-70.8%) and the lowest cell contamination (leukocytes 0.1-0.2 x 10(8), red cells 0.2-0.3 x 10(8) per concentrate) were obtained with whole blood stored for 1 h and BC for 2-4 h before resuspension by 30 min...
IMPLANTATION OF AUTOLOGOUS SKIN FIBROBLAST GENETICALLY MODIFIED TO SECRETE CLOTTING FACTOR IX PARTIALLY CORRECTS THE HEMORRHA FACTORIMPLANTATIONOFAUTOLOGOUSSKINFIBROBLASTGENETICALLYMODIFIEDTOSECRETECLOTTINGFACTORIXPARTIALLYCORRECTSTHEHEMORRHAGICTENDENCIESIN...邱信芳卢大儒周洁民王健民杨建民孟沛霖薛京伦中华医学杂志:英文版...
Tarzia V, Bottio T, Buratto E, Spiezia L, Simioni P, Gerosa G. The hazard of comparing apples and oranges: the proper indication for the use of recombinant activated clotting factor VII in cardiac surgery. J Thorac Cardiovasc Surg 2011; 142: 1588-1589; author reply 1589 [PMID: 22093717...
We hypothesized that replacing deficient factor VIII or IX within the injured joint capsule of mice with hemophilia A (FVIII / ) or hemophilia B (FIX / ), respectively, would decrease the progression of synovitis. We developed a bleeding model consisting of a unilateral knee joint capsule ...